Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUM 001

Next Previous
Drug Profile

AUM 001

Alternative Names: AUM-001; ETC 206; ETC-1907206

Latest Information Update: 21 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agency for Science, Technology and Research; Duke-NUS Graduate Medical School Singapore
  • Developer AUM Biosciences
  • Class Antineoplastics
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • No development reported Chronic myeloid leukaemia; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Jun 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
  • 02 Jun 2023 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 14 Apr 2023 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in Australia (PO) (NCT05462236)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top